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Background: PALB2 has emerged as a breast cancer susceptibility gene. Mutations in PALB2 have been identified in
almost all breast cancer populations studied to date, but the rarity of these mutations and lack of information
regarding their penetrance makes genetic counseling for these families challenging. We studied BRCA1/2 -negative
breast and/or ovarian cancer families to a) assess the contribution of PALB2 mutations in this series and b) identify
clinical, pathological and family history characteristics that might make PALB2 screening more efficient.
Methods: The coding region of the PALB2 gene was analyzed in 175 probands with family histories of breast
and/or ovarian cancer ascertained from a single Canadian institution in Eastern Ontario.
Results: We identified 2 probands with PALB2 mutations that are known or strongly considered to be pathogenic
and 3 probands with missense mutations that are possibly pathogenic. One of the identified truncating mutations
[c.3113G > A (p.Gly1000_Trp1038del – major product)], has been previously described while the other four
mutations [c.3507_3508delTC (p.H1170Ffs*19), c.1846G > C (p.D616H), c.3418 T > G (p.W1140G), c.3287A > G
(p.N1096S)] have not been previously reported. Loss of heterozygosity was detected in two breast tumors from
one c.3507_3508delTC mutation carrier but not in other available tumors from that family or in tumors from carriers
of other mutations.
Conclusions: PALB2 mutation screening identifies a small, but significant number of mutations in BRCA1/2 -negative
breast and/or ovarian cancer families. We show that mutations are more likely to be found in families with three or
more breast cancers as well as other BRCA2-related cancers. In our cohort, both clearly pathogenic mutations were
identified in premenopausal breast cancer cases (2/77, 2.6%). Testing should be preferentially offered to affected
women from such families.
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Since first being identified as a BRCA2-interacting pro-
tein, Partner and Localizer of BRCA2 (PALB2) has been
shown to also interact with BRCA1, effectively bridging
these two well-known high-risk breast cancer suscepti-
bility genes and aiding to regulate their function in DNA
damage response and homologous recombination [1,2].* Correspondence: etomiak@cheo.on.ca
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unless otherwise stated.Not surprisingly, PALB2 has emerged in the last few
years as an important breast cancer susceptibility gene
in its own right (reviewed in [3]).
Germline mutations in PALB2 have been identified
worldwide (reviewed in [4]), albeit rarely (1–4% of breast
cancer families negative for BRCA1/BRCA2 mutations),
and these mutations are associated with an increased
risk of breast cancer that varies from approximately 2.3
to as high as ~6.0 depending on the mutations being
studied and the populations under investigation [5-7].
While the degree of breast cancer susceptibility is still
unclear, some studies examining recurrent PALB2Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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have demonstrated a risk and penetrance as high as
those arising from BRCA2 mutations [6,7].
Similar to mutations in BRCA1 and BRCA2, the risks
associated with monoallelic mutations in PALB2 seem to
extend beyond breast cancer. To date, the spectrum of
malignancies associated with PALB2 mutations remains
unclear, however mutations confer increased risks for
pancreatic cancer [8] and possibly ovarian cancer [9].
With the advent and increasing use of multiplex panels
that test PALB2 alongside the BRCA genes [10], the great-
est barrier for the implementation of PALB2 analysis into
the clinic is no longer its testing efficiency but instead the
lack of clear information and recurrence risks with which
to counsel patients should a mutation be identified. Deter-
mining PALB2 mutation status is important, however, as
it may allow female relatives of mutation positive patients
the opportunity to make informed decisions about options
to mitigate their elevated risk for disease. Also, new effec-
tive targeted therapeutic options are becoming available
(PARP inhibitors) that have shown promising results in
in vitro studies with PALB2 deficient cells exhibiting a
defect in homologous repair [11].
Given that in order to determine clear criteria for
genetic testing, we must first identify the likelihood of
finding mutations in different populations, here we report
our analysis of PALB2 in 175 breast and ovarian cancer
pedigrees from a clinical cohort in Eastern Ontario,
Canada, in which BRCA1 and BRCA2 testing failed to
identify any causal variants.
Materials and methods
Cases and case selections
Participants were accrued from May 2009 to July 2012
at the Eastern Ontario Regional Genetics Program at the
Children’s Hospital of Eastern Ontario. For this investi-
gation, we selected participants affected with breast or
ovarian cancer who had been previously screened for
BRCA1 and BRCA2 mutations and excluded individuals
with pathogenic mutations. Most individuals (169/175)
were tested for BRCA1 and BRCA2 mutations by denatur-
ing high-performance liquid chromatography, enhanced
mismatch mutation analysis or sequencing. In six of eight
individuals of Ashkenazi Jewish (AJ) descent, testing was
limited to screening for the three common AJ mutations
accounting for 98% of mutations in that population. Two
individuals of AJ decent underwent full gene analysis, and
163/175 individuals were screened by MLPA for large in-
sertions/deletions. Two separate cohorts of patients were
specified: 1) those recruited May 2009 to September 2010,
who were affected with breast or ovarian cancer, met On-
tario provincial criteria for BRCA1 and BRCA2 genetic
testing, and had a minimum BRCAPRO score of 0.10; 2)
those recruited September 2010 to July 2012, who metselect Ontario provincial criteria, were affected with breast
or ovarian cancer, and had no BRCAPRO requirement
(see Supplemental Materials for detailed list of Ontario
Criteria, Additional file 1: Table S1). The criteria for study
entry was changed to make sure we did not miss persons
with a family history of pancreas cancer that might not
otherwise be included on the basis of the BRCAPRO
score.
Enrollment of probands, ascertainment of families and
PALB2 gene analysis proceeded identically for each par-
ticipant. Their respective geneticist or genetic counselor
initially identified potential participants, and informed
consent was obtained for those meeting criteria and inter-
ested in enrolling. In total, 195 patients were originally ac-
crued. Of these, 13 participants showed initial interest yet
failed to submit a blood sample, 4 were found to not meet
selection criteria following enrollment. Of the 178 partici-
pants tested, in three cases the DNA sample was of insuf-
ficient quality. Therefore, of the 195 participants originally
enrolled, 175 were eligible and able to be tested. Charac-
teristics of the study participants are given in Table 1.
Characteristics of breast tumor specimens are given in
Additional file 1: Table S2.
Of the 13 patients who were diagnosed with ovarian
cancer, four of whom were also diagnosed with breast
cancer, over half (7/13) of the ovarian cancers were pa-
pillary serous or serous morphology. Two probands had
ovarian cancers with mucinous morphology. The other 4
participants were affected with one case each of clear
cell carcinoma, carcinosarcoma, mixed mucinous and
endometrioid cystadenocarcinoma, and borderline papil-
lary serous tumor of low malignant potential.
Of the 24 cases of female multiple primary breast can-
cer, 16 cases were bilateral metachronous, 5 cases were
bilateral synchronous, and 3 were synchronous and in the
same breast.
Three hundred and eleven index cases from suspected
hereditary breast and ovarian cancer families from
Northern Portugal, all Caucasian, were screened for the
N1096S variant only. Cases included 256 female breast
cancer patients with an average age at diagnosis of 42.6 yrs,
24 male breast cancer cases and 31 index cases with other
(or no) cancer.
Molecular methods
a. PALB2 sequencing and MLPA
We screened the 13 coding exons of PALB2
(NCBI reference sequences NG_007406.1 and
NM_024675.3), by high-resolution melting (HRM)
analysis using the LightScanner instrument (Idaho
Technologies Inc., Utah, USA). The PCR reactions
for HRM were performed in 96 well plates from Bio
Rad (Ontario, Canada) using the mastermix and the
Table 1 Characteristics of 175 probands with clinical diagnoses of female unilateral breast cancer, female multiple
primary breast cancer, male breast cancer or ovarian cancer
Female unilateral Female multiple primary Male breast cancer Ovarian cancer
Number of probands: 126 24 12 13*
Age at Diagnosis (N) (%) (N) (%) (N) (%) (N) (%)
20-29 7 5.6 0 0 0 0 1 7.7
30-39 26 20.6 5 20.8 0 0 1 7.7
40-49 44 34.9 13 54.2 3 25.0 5 38.5
50-59 30 23.8 6 25.0 2 16.7 0 0
60-69 16 12.7 0 0 3 25.0 5 38.5
70 and over 3 2.3 0 0 4 33.3 1 7.7
Mean (years) 47.1 43.4 60.8 51.3
Range (years) 23-78 31-58 43-76 23-76
Mean time from diagnosis (years) 4.7 12.4 1.8 10.3
Ethnicity** (N) (%) (N) (%) (N) (%) (N) (%)
British Isles 47 37.3 8 33.3 6 50.0 5 38.5
French Canadian 27 21.4 5 20.8 1 8.3 5 38.5
Other European 19 15.1 7 29.2 2 16.6 2 15
Ashkenazi Jewish 8 6.3 1 4.2 0 0 0 0
Asian 4 3.2 0 0 1 8.3 0 0
Mixed Ethnicity 16 12.7 3 12.5 1 8.3 0 0
Other or unknown 5 4.0 0 0 1 8.3 1 7.7
*Includes 4 probands affected with both breast and ovarian cancer.
**All self-reported ethnicities from the side of the family eligible for BRCA1 and BRCA2 sequencing based on Ontario guidelines.
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(Ontario, Canada). Following amplification, the
plates were then transferred to the LightScanner
instrument and the melting curves were analysed
with the software provided by Idaho Technologies.
This technique was used as a presequencing
selection for amplicons harboring variants. Samples
having a different melting curve than the majority
were analysed by Sanger sequencing. The primer
sequences and the protocol for amplification have
been previously published [12]. Samples were also
screened for large insertions/deletions overlapping
coding regions that would be missed using the PCR-
based method above using a commercially available
Multiplex Ligation-dependent Probe Amplification
mix (MRC-Holland, Amsterdam, Netherlands) using
the supplier’s recommended protocol.
b. c.3287A >G (p.N1096S) screening
Screening for the c.3287A > G (N1096S) variant in
311 Portuguese index cases was performed using
KASPar® SNP genotyping on demand by
KBiosciences on a Roche LightCycler® 480
Real-Time PCR System.
c. LOH testing in tumor samples
DNA extracted from formalin-fixed,
paraffin-embedded (FFPE) tumors that weremacro-dissected to enrich for tumor cells was used
to perform loss of heterozygosity (LOH) analysis in
mutation carriers. The region surrounding each
variant was amplified by PCR using variant-specific
primers (Additional file 1: Table S3) that were
designed using the Primer3 software
(http://bioinfo.ut.ee/primer3-0.4.0/). Amplicons
were analysed by Sanger sequencing.
d. Expression analysis of c.3507_3508delTC
(p.H1170Ffs*19)
Lymphoblastoid cell lines (LCLs) harboring the
c.3507_3508delTC (p.H1170Ffs*19) mutation were
grown in Dulbecco’s Modified Iscove’s Media
(Life Technologies Burlington, Ontario, Canada).
RNA was extracted from 10 million cells using
Trizol reagent (Life Technologies Burlington,
Ontario, Canada) following the manufacturer’s
protocol. 1 ug of RNA was used for reverse
transcription (Qiagen California, USA) following
the manufacture’s protocol, followed by cDNA
amplification of PALB2. The primers used were:
forward primer, 5’-GCAGGCTGGCAGGTTCCT-3’
(covers the junction of exon 12 and 13 of
PALB2 in the cDNA); and reverse primer,
5’-CATCCAAGATCAGTGGTGCTA-3’
(in the 3’UTR).
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Mutation analysis of PALB2 identified two monoallelic
deleterious mutations in 2/126 (1.6%) women with diagno-
ses of unilateral breast cancer. Of the two mutations,
c.3113G >A has been previously reported by several
groups and is thought to be a founder mutation from the
United Kingdom [5,7,12-15]. It has been shown to produce
three distinct transcripts resulting in p.Gly1000_Trp1038-
del (56%), p.Thr1029Ilefs*2 (40%) and p.Trp1038* (4%)
[12] (Additional file 1: Figure S1). The frameshift mutation













Figure 1 Pedigree and LOH Testing in Tumors of c.3113G> A Mutation
Circles = females; Squares =males. Filled symbols = affected with cancer. Slash
d. = death, numbers denote age, the arrow denotes the proband. (B) Loss of
are still present in the tumor. (C) Hematoxylin-eosin stain of the tumor tissueThe index case with the PALB2 c.3113G > A mutation
(Figure 1A) was of British descent and had been diagnosed
with invasive ductal (ER+, PR+, HER2-) breast cancer at
36 years of age. Evaluation of her mother revealed that the
mutation was most likely paternally inherited. Her pater-
nal family history is significant for an aunt diagnosed with
pancreatic cancer at 60 and two first cousins with breast
cancer diagnosed in their 40s.
The index case with the PALB2 c.3507_3508delTC
(p.H1170Ffs*19) (Figure 2A) mutation was of British des-
cent and had been diagnosed with invasive ductal (ER+,


















Family. (A) Pedigree of the family carrying the c.3113G > A mutation.
ed symbols = deceased. +/+ =wild-type; +/− = heterozygous carrier;
heterozygosity analysis of the proband’s breast cancer shows both alleles
analyzed in panel B.
Figure 2 Pedigree and LOH Testing in Tumors of c.3507_3508delTC Mutation Family. (A) Pedigree of the family carrying the
c.3507_3508delTC mutation. Circles = females; Squares =males. Filled symbols = affected with cancer. Slashed symbols = deceased. +/+ =wild-type;
+/− = heterozygous carrier; numbers denote age, the arrow denotes the proband. (B) Loss of heterozygosity (LOH) analysis in tumor tissue from
mutation carriers. The reverse sequence is shown. A hematoxylin-eosin stain of the tumor tissue analyzed is shown to the right of each chromatogram.
I) Normal tissue showing the heterozygous mutation; II) Tumor tissue from the proband, (no LOH); III) Tumor tissue from the proband’s sister (no LOH);
IV) Tumor tissue from the left breast of the proband’s mother (loss of the wild-type allele); V) Tumor tissue from the right breast of the proband’s
mother (loss of the wild-type allele).
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proband’s relatives, from whom genetic material was
available; two individuals (the proband’s mother and sis-
ter) affected with breast cancer were carriers of the family
mutation. The proband’s unaffected sister, who has a
daughter with a diagnosis of malignant melanoma at
age 11, was also found to carry the familial mutation. An
unaffected uncle was found to not carry the familial
mutation.
Three additional missense variants predicted to be pa-
thogenic by Sorting Intolerant From Tolerant (SIFT)
[16], Polymorphism Phenotyping (Polyphen) [17], Muta-
tionTaster [18] and Consensus Deleteriousness (Condel)
[19] were identified (Table 2). The first, c.1846G > C
(p.D616H) was observed in a proband diagnosed with
unilateral breast cancer from a French Canadian family
(Additional file 1: Figure S2A). The second, c.3418 T > G
(p.W1140G), was observed in a proband diagnosed withunilateral breast cancer from a French Canadian and
British family (Additional file 1: Figure S2B). Finally, the
third variant, c.3287A > G (p.N1096S), was identified in
a proband diagnosed with bilateral breast cancer from a
Portuguese family (Additional file 1: Figure S2C). Given
the previously reported existence of a Portuguese foun-
der mutation in BRCA2 [20], we considered the pos-
sibility that this novel PALB2 variant was a founder
mutation and subsequently analyzed for its presence in a
larger Portuguese series. The c.3287A > G (p.N1096S)
variant was not observed in an additional 311 Caucasian
index cases primarily from Northern Portugal who were
negative for BRCA1 and BRCA2 mutations. While these
variants are possibly pathogenic functionally, c.1846G > C
(p.D616H) does not appear to segregate with the disease,
and DNA from additional affected individuals was not
available to perform informative segregation analysis of
the other two variants. In total, 86 participants, including
Table 2 Summary of identified variants and tumor characteristics of the PALB2 carriers
Tumor characteristics In silico analysis
Mutation Exon Age Type Stage ER PR Her2 Previously reported? SIFT Polyphen




c.3507_3508delTC 12 44 IDC 1 Pos Pos Pos no
p.H1170Ffs*19
Missense c.1846G > C 4 25 IDC 1 U U U no 0.02 1.00
p.D616H
c.3418 T > G 12 32 IDC 1 Pos Pos Pos no 0.00 1.00
p.W1140G
c.3287A > G 10 50/58 DCIS/IDC 0/2 NP/Pos NP/Pos NP/U no 0.00 1.00
p.N1096S
ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2; IDC = infiltrating ductal carcinoma; DCIS = ductal
carcinoma in situ; U = unknown; Pos = positive; Neg = negative; NP = not performed.
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identified to carry a PALB2 variant (Additional file 1:
Table S4).
We performed loss of heterozygosity (LOH) analysis on
available breast tumors from the five families. Tumor
tissue was not available for testing for any c.3287A >G
(p.N1096S) and c.1846G >C (p.D616H) carriers. LOH was
observed in both the left and right breast tumors from the
mother carrying the c.3507_3508delTC (p.H1170Ffs*19)
mutation, but none of the other tumors showed loss of
the wild-type allele [Figures 1B and 2B, data not shown
for the tumor from the proband with c.3418 T >G
(p.W1140G)]. These results are consistent with previous
observations that LOH is an inconsistent feature of PALB2
tumors, even among tumors carrying identical predis-
posing mutations [13,14,21,22].
In 175 probands tested, we identified PALB2 mutations
that can alter the length of the PALB2 protein. The first,
c.3113G >A, was previously identified in multiple un-
related families from Australia, the United States and the
UK and is associated with an estimated 91% (95% CI =
44–100) cumulative risk of breast cancer to age 70 [7,23].
As our family with c.3113G > A is of British descent, our
results support the hypothesis that c.3113G > A is a
founder mutation in the British population. Most recently,
Teo et al. [23] identified this particular mutation in 8 of
871 (0.92%) probands from “high-risk” breast and/or
ovarian cancer families evaluated in familial cancer clinics
in Australia and New Zealand.
The c.3507_3508delTC (p.H1170Ffs*19) mutation is
located in the final exon (exon 13) of PALB2. Sequen-
cing of RNA from cultured LCLs showed expression of
the mutant allele (Additional file 1: Figure S3), indicating
that mRNA derived from the mutated allele is notsubject to nonsense-mediated decay. The frameshift intro-
duces 18 new amino acids that are not seen in the native
protein (Additional file 1: Figure S1B), resulting in a
mutant protein of 1187 amino acids, compared to 1186
amino acids in the wild-type protein. The predicted struc-
ture of PALB2 includes an amino-terminal coiled-coil
structure and a carboxy-terminal WD40-repeats motif
that has the characteristics of a seven-bladed beta-pro-
peller, a domain commonly involved in protein-protein
interactions. The WD40-repeats domain on amino acids
836–1186 provides a binding site for the N-terminus of
BRCA2 [24]. Mutations in this region, even if they do not
result in nonsense-mediated decay, may lead to altera-
tion of the structure of WD40-repeats (Additional file 1:
Figure S1) [5], and many are known to be pathogenic.
Thus, independent of the genetic data we present here
(segregation and LOH), there is fairly strong a priori
evidence that this novel mutation c.3507_3508delTC
(p.H1170Ffs*19) we describe here is deleterious, probably
as a result of disruption of the BRCA1-PALB2-BRCA2
interaction, resulting in defective homologous repair of
double-stranded breaks.
In terms of immunohistochemical features seen in the
tumors of our participants with pathogenic or suspected
pathogenic PALB2 mutations, although earlier studies per-
formed in Finnish, French Canadian and other European
populations suggested a possible overrepresentation of
triple negative (basal-like) tumors in PALB2-related breast
cancers [4,25,26], our overall results support more recent
studies of Australasian breast cancer families that have
not found any association between PALB2 mutations and
hormone-receptor negative breast tumors [27,28]. Al-
though the number of probands with multiple breast pri-
maries in our series is small (24 cases) it is interesting
Hartley et al. Hereditary Cancer in Clinical Practice 2014, 12:19 Page 7 of 9
http://www.hccpjournal.com/content/12/1/19that, of the tumors that are available for hormone receptor
and HER2 analysis in this specific subgroup of patients, an
increased proportion (24%) had triple negative phenotype
(Additional file 1: Table S2). Further studies in larger co-
horts will be necessary to determine whether the triple
negative phenotype is overrepresented in PALB2 carriers
with specific (founder) mutations or specific clinical pre-
sentations (early onset or bilateral disease).
Pathogenic or likely pathogenic PALB2 mutations were
observed in 2 of 89 families (2.2%) with 3 or more cases
of breast cancer (Table 3A). Although not statistically
significant, these numbers suggest a greater than 1%
chance of identifying mutations in PALB2 in families
with 3 or more breast cancer cases where BRCA1/2 mu-
tations have been excluded.
The majority of probands with a pathogenic or sus-
pected pathogenic PALB2 mutation had a first or second-
degree relative with breast cancer (Table 3B), and if they
did not, had a first degree or second-degree relative with a
tumor suspected to be associated with a BRCA2 or PALB2
mutation (Additional file 1: Figure S2). Thus it does not
appear to be worthwhile to screen families for PALB2 mu-
tations if the proband does not have close relatives who
are affected by breast cancer or a BRCA2/PALB2 related
cancer.
Similar to the observations of Casadei et al. [13], the
cancer profiles of the two PALB2 mutation families
seemed similar to cancer profiles of BRCA2 families;
including relatives affected with pancreatic cancer and
melanoma. The frequencies of these cancers in theTable 3 Total patient population screened
(A) Number of Breast Cancer Cases in Families
Total 5 BC in family 4 BC in famil
Female Unilateral Breast 126 19 25
Female Multiple Primary Breast 24 1 4
Male Breast 12 0 0
Breast and Ovarian 4 1 1
Ovarian 9 0 2
Total screened 175 21 32
PALB2 mutations* 2 0 0
B) Proximity to Breast Cancer Cases in Families
Total FDR with BC
Female Unilateral Breast 126 79
Female Multiple Primary Breast 24 11
Male Breast 12 2
Breast and Ovarian 4 2
Ovarian 9 4
Total screened 175 98
PALB2 mutations* 2 1
*Only the two definitely deleterious mutations were included in these tables. BC = b
TDR = third degree relative.family histories of our cohort are described in Additional
file 1: Table S5A and Additional file 1: Table S5B, re-
spectively. Multiple studies have identified PALB2 mu-
tations in familial pancreatic cancer probands, several of
which were found to have family histories including cases
of breast cancer [8,29-31]. It should be noted that these
mutations occur at relatively low frequencies (0–4%),
which depend on the population being studied [8,32].
Whether or not PALB2 mutations are associated with
an increased risk of melanoma remains unclear and fur-
ther studies are needed. Rahman et al. [5] described a
proband with a truncating PALB2 mutation (p.Y1183X)
and diagnoses of melanoma at 47 years of age and breast
cancer at 56 years. To the best of our knowledge, this is
the only case in the literature describing melanoma in
PALB2 mutation carriers. In addition, Sabbaghian et al.
[33] did not find a single PALB2 mutation in 53 cases of
familial melanoma. While we do not know PALB2 status
in the niece of our c.3507_3508delTC proband (given
her young age she was not yet offered testing), the
extremely young age of malignant melanoma diagnosis
(at 11 years) is intriguing.
The contribution of PALB2 mutations to ovarian can-
cer risk also remains uncertain with previous studies
being conflicting (reviewed in 3,4). Some groups have
observed an increased likelihood for PALB2 mutation
carriers to have relatives affected with ovarian cancer, al-
beit this was not a statistically significant finding [13].
One study which used massively parallel sequencing to
examine the burden of loss of function mutations iny 3 BC in family 2 BC in family 1 BC in family 0 BC in family
31 39 12 0
2 12 5 0
1 4 7 0
0 1 1 0
2 2 1 2
36 58 26 2
2 0 0 0








reast cancer; FDR = first degree relative; SDR = second degree relative;
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mary ovarian, peritoneal, or fallopian tube carcinoma
identified 2 PALB2 mutations in 360 probands tested
[9]. It should be noted that the majority (139/175) of the
families we screened did not contain any reported cases
of ovarian cancer (Additional file 1: Table S5C).
Both the truncating pathogenic and the non-truncating
frameshifting (and likely pathogenic) mutation in PALB2
were identified amongst the 77 women diagnosed with
premenopausal (<50 years old) unilateral breast cancer.
Therefore, 2/77 (2.6%) mutations were identified in this
particular group of women. Data from other reported
series also suggests that PALB2 mutations may be prefer-
entially identified in premenopausal women, but not all
studies report on the number of individuals in the series
with diagnoses under the age of 50. Rahman et al. [5]
noted that the median age of diagnosis for those with
PALB2 mutations in their study was 46 years, while those
individuals without a PALB2 mutation had a median age
at diagnosis of 49 years. In their cohort, 8/10 probands
with pathogenic mutations had their breast cancer diag-
nosed at or less than 50 years of age. In the case series re-
ported by Southey et al., 4/5 had breast cancer diagnosed
at or less than 50 years of age [7]. In the study of cases
with bilateral breast cancer reported by Tischkowitz [12],
the median age at diagnosis of first breast cancer in the 5
women identified to carry a pathogenic mutation was
46 years. Notably in their series, none of the probands had
an additional young onset case in the family. Taken to-
gether, these data suggest that it may be reasonable to
preferentially offer PALB2 clinical testing to BRCA1/2-
negative breast and/or ovarian cancer families with mul-
tiple cases of breast cancer, including at least one case of
premenopausal breast cancer.
Finally, although the sample size in our study is small,
the presence of PALB2 mutations in our cohort confirms
that they are present at low frequency in familial breast
cancer cases. It is also possible that deep intronic muta-
tions may exist which would have escaped detection
with our screening methodology.
Conclusion
In 175 probands from a clinic based series of breast and/or
ovarian cancer families with no detectable BRCA1/BRCA2
mutations, we have identified two mutations in PALB2:
one, c.3113G >A, is known to be deleterious and the other,
c.3507_3508delTC (p.H1170Ffs*19), is likely to be deleteri-
ous. Both probands had family histories in which three or
more individuals had been diagnosed with breast cancer.
Both of these two families also had a family member with a
diagnosis of another BRCA2-related cancer. PALB2 muta-
tions are not as frequent in the population as BRCA1 and
BRCA2 mutations; however, the role of PALB2 in breast
cancer susceptibility is still significant, some studiessuggesting that particular PALB2 mutations may pre-
dispose individuals to breast cancer to a similar extent as
BRCA2. It therefore warrants knowing who should be
tested.
This study supports the notion that PALB2 mutations
are present at a relatively low frequency in hereditary
breast cancer cases and that in women with breast can-
cer, who have a family history including 3 or more cases
of breast cancer, PALB2 testing may identify a mutation
in >2% of cases and restricting testing to affected pre-
menopausal women in such families may capture the
vast majority of these mutations. Clinical testing could
also be considered in the context of another BRCA2-re-
lated malignancy, and when at least one family member
is diagnosed with premenopausal breast cancer.
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